Drug profile · INN
amisulpride
AMISULPRIDE SANDOZ PHARMA
amisulpride (AMISULPRIDE SANDOZ PHARMA) is a serotonin (5-ht) receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — amisulpride
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 9
- Data quality
- 0.84
Quick answer
amisulpride (AMISULPRIDE SANDOZ PHARMA) is a serotonin (5-ht) receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin (5-HT) receptor antagonist
Primary target: Dopamine receptors; D2 & D3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Frequently asked questions
What is amisulpride?
amisulpride (AMISULPRIDE SANDOZ PHARMA) is a serotonin (5-ht) receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for amisulpride?
AMISULPRIDE SANDOZ PHARMA is a marketed brand name for amisulpride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of amisulpride?
amisulpride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.